Literature DB >> 26080402

Reduction of toxic RNAs in myotonic dystrophies type 1 and type 2 by the RNA helicase p68/DDX5.

Karlie Jones1, Christina Wei2, Benedikt Schoser3, Giovanni Meola4, Nikolai Timchenko5, Lubov Timchenko6.   

Abstract

Myotonic dystrophies type 1 (DM1) and type 2 (DM2) are neuromuscular diseases, caused by accumulation of CUG and CCUG RNAs in toxic aggregates. Here we report that the increased stability of the mutant RNAs in both types of DM is caused by deficiency of RNA helicase p68. We have identified p68 by studying CCUG-binding proteins associated with degradation of the mutant CCUG repeats. Protein levels of p68 are reduced in DM1 and DM2 biopsied skeletal muscle. Delivery of p68 in DM1/2 cells causes degradation of the mutant RNAs, whereas delivery of p68 in skeletal muscle of DM1 mouse model reduces skeletal muscle myopathy and atrophy. Our study shows that correction of p68 may reduce toxicity of the mutant RNAs in DM1 and in DM2.

Entities:  

Keywords:  CUG repeats; RNA foci; myotonic dystrophy; p68 RNA helicase

Mesh:

Substances:

Year:  2015        PMID: 26080402      PMCID: PMC4491770          DOI: 10.1073/pnas.1422273112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  The ATPase, RNA unwinding, and RNA binding activities of recombinant p68 RNA helicase.

Authors:  Youliang Huang; Zhi-Ren Liu
Journal:  J Biol Chem       Date:  2002-01-31       Impact factor: 5.157

Review 2.  RNA-dominant diseases.

Authors:  Robert J Osborne; Charles A Thornton
Journal:  Hum Mol Genet       Date:  2006-10-15       Impact factor: 6.150

Review 3.  Myotonic dystrophy: the role of RNA CUG triplet repeats.

Authors:  L T Timchenko
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

4.  Novel proteins with binding specificity for DNA CTG repeats and RNA CUG repeats: implications for myotonic dystrophy.

Authors:  L T Timchenko; N A Timchenko; C T Caskey; R Roberts
Journal:  Hum Mol Genet       Date:  1996-01       Impact factor: 6.150

5.  Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat.

Authors:  A Mankodi; E Logigian; L Callahan; C McClain; R White; D Henderson; M Krym; C A Thornton
Journal:  Science       Date:  2000-09-08       Impact factor: 47.728

6.  Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy.

Authors:  J W Miller; C R Urbinati; P Teng-Umnuay; M G Stenberg; B J Byrne; C A Thornton; M S Swanson
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

7.  The structural basis of myotonic dystrophy from the crystal structure of CUG repeats.

Authors:  Blaine H M Mooers; Jeremy S Logue; J Andrew Berglund
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-03       Impact factor: 11.205

8.  Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy.

Authors:  L T Timchenko; J W Miller; N A Timchenko; D R DeVore; K V Datar; L Lin; R Roberts; C T Caskey; M S Swanson
Journal:  Nucleic Acids Res       Date:  1996-11-15       Impact factor: 16.971

9.  Hairpin structure-forming propensity of the (CCTG.CAGG) tetranucleotide repeats contributes to the genetic instability associated with myotonic dystrophy type 2.

Authors:  Ruhee Dere; Marek Napierala; Laura P W Ranum; Robert D Wells
Journal:  J Biol Chem       Date:  2004-07-29       Impact factor: 5.157

10.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

View more
  14 in total

1.  Correction of GSK3β at young age prevents muscle pathology in mice with myotonic dystrophy type 1.

Authors:  Christina Wei; Lauren Stock; Leila Valanejad; Zachary A Zalewski; Rebekah Karns; Jack Puymirat; David Nelson; David Witte; Jim Woodgett; Nikolai A Timchenko; Lubov Timchenko
Journal:  FASEB J       Date:  2018-01-05       Impact factor: 5.191

2.  Overexpression of Staufen1 in DM1 mouse skeletal muscle exacerbates dystrophic and atrophic features.

Authors:  Tara E Crawford Parks; Kristen A Marcellus; Christine Péladeau; Bernard J Jasmin; Aymeric Ravel-Chapuis
Journal:  Hum Mol Genet       Date:  2020-08-03       Impact factor: 6.150

3.  Pharmacological and physiological activation of AMPK improves the spliceopathy in DM1 mouse muscles.

Authors:  Aymeric Ravel-Chapuis; Ali Al-Rewashdy; Guy Bélanger; Bernard J Jasmin
Journal:  Hum Mol Genet       Date:  2018-10-01       Impact factor: 6.150

Review 4.  RNA toxicity and foci formation in microsatellite expansion diseases.

Authors:  Nan Zhang; Tetsuo Ashizawa
Journal:  Curr Opin Genet Dev       Date:  2017-02-14       Impact factor: 5.578

5.  Correction of Glycogen Synthase Kinase 3β in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice.

Authors:  Mei Wang; Wen-Chin Weng; Lauren Stock; Diana Lindquist; Ana Martinez; Genevieve Gourdon; Nikolai Timchenko; Mike Snape; Lubov Timchenko
Journal:  Mol Cell Biol       Date:  2019-10-11       Impact factor: 4.272

6.  (CCUG)n RNA toxicity in a Drosophila model of myotonic dystrophy type 2 (DM2) activates apoptosis.

Authors:  Vildan Betul Yenigun; Mario Sirito; Alla Amcheslavky; Tomek Czernuszewicz; Jordi Colonques-Bellmunt; Irma García-Alcover; Marzena Wojciechowska; Clare Bolduc; Zhihong Chen; Arturo López Castel; Ralf Krahe; Andreas Bergmann
Journal:  Dis Model Mech       Date:  2017-06-16       Impact factor: 5.758

7.  Receptor and post-receptor abnormalities contribute to insulin resistance in myotonic dystrophy type 1 and type 2 skeletal muscle.

Authors:  Laura Valentina Renna; Francesca Bosè; Sara Iachettini; Barbara Fossati; Lorenzo Saraceno; Valentina Milani; Roberto Colombo; Giovanni Meola; Rosanna Cardani
Journal:  PLoS One       Date:  2017-09-15       Impact factor: 3.240

Review 8.  Overlapping mechanisms of lncRNA and expanded microsatellite RNA.

Authors:  Sara J Johnson; Thomas A Cooper
Journal:  Wiley Interdiscip Rev RNA       Date:  2020-11-16       Impact factor: 9.957

9.  Staufen1 Regulates Multiple Alternative Splicing Events either Positively or Negatively in DM1 Indicating Its Role as a Disease Modifier.

Authors:  Emma Bondy-Chorney; Tara E Crawford Parks; Aymeric Ravel-Chapuis; Roscoe Klinck; Lynda Rocheleau; Martin Pelchat; Benoit Chabot; Bernard J Jasmin; Jocelyn Côté
Journal:  PLoS Genet       Date:  2016-01-29       Impact factor: 5.917

10.  Staufen1s role as a splicing factor and a disease modifier in Myotonic Dystrophy Type I.

Authors:  Emma Bondy-Chorney; Tara E Crawford Parks; Aymeric Ravel-Chapuis; Bernard J Jasmin; Jocelyn Côté
Journal:  Rare Dis       Date:  2016-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.